Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment guidelines recommend drug treatment to prevent fractures for some postmenopausal women who have low bone mass (osteopenia) but do not have osteoporosis or a history of clinical fractures. OBJECTIVE: To estimate the societal costs and health benefits of alendronate drug treatment to prevent fractures in postmenopausal women with osteopenia. DESIGN: Markov model with 8 health states: no fracture, post-distal forearm fracture, post-clinical vertebral fracture, post-radiographic (but clinically inapparent) vertebral fracture, post-hip fracture, post-hip and vertebral fractures, post-other fracture, and death. DATA SOURCES: Population-based studies of age-specific fracture rates and costs, prospectively measured estimates of disutility after fractures, and the Fracture Intervention Trial of alendronate versus placebo to prevent fracture. TARGET POPULATION: Postmenopausal women 55 to 75 years of age with femoral neck T-scores between -1.5 and -2.4. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTIONS: Five years of alendronate therapy or no drug treatment. OUTCOME MEASURES: Costs, quality-adjusted life-years, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: For women with no additional fracture risk factors, the cost per quality-adjusted life-year gained ranged from 70,000 dollars to 332,000 dollars, depending on age and femoral neck bone density. RESULTS OF SENSITIVITY ANALYSES: Results were sensitive to changes in fracture risk reduction attributable to alendronate and alendronate cost. LIMITATIONS: Results apply only to postmenopausal white women residing in the United States. CONCLUSION: Alendronate therapy for postmenopausal women with femoral neck T-scores better than -2.5 and no history of clinical fractures or other bone mineral density-independent risk factors for fracture is not cost-effective, assuming U.S. costs of alendronate and currently available estimates of alendronate efficacy in osteopenic women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443 · cited 1×
“This database captures almost all health care utilization within Olmsted County, Minnesota (13).”
BackgroundTen Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Updated Data on Proximal Femur Bone Mineral Levels of US Adults
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., Johnston Jr, C. C., & Lindsay, R. (1998) · Osteoporosis International · doi:10.1007/s001980050093 · Cited by 1,121 · cited 4×
“114 is the pooled SD of femoral neck BMD calculated from NHANES III data for nonHispanic white women older than 50 years of age (10).”
BackgroundMethodInfluentialVariations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059 · cited 1×
“QALYs Associated with Each Health State For 1 year in the no fracture state, we used a QALY value estimated with the EuroQoL questionnaire (EQ-5D) in representative samples of the British and Swedish populations age 60 to 69 years (23, 24, 33).”
MethodProbabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach
Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. (1985) · Medical Decision Making · doi:10.1177/0272989x8500500205 · Cited by 860 · cited 1×
“We also performed probabilistic sensitivity analyses by using 2-stage Monte Carlo simulations (36, 37).”
MethodWillingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Swedish population health-related quality of life results using the EQ-5D
Burström, K., Johannesson, M., & Diderichsen, F. (2001) · Quality of Life Research · doi:10.1023/a:1013171831202 · Cited by 664
Cited by
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA
Dawson-Hughes, B., Tosteson, A. N. A., Melton, L. J., Baim, S., Favus, M. J., Khosla, S., & Lindsay, R. L. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0559-5 · Cited by 427
“Thus, the 10-year fracture probability in an average-risk 50-year-old white woman is quite low [60], suggesting that treatment of such patients will not be costeffective [13, 61].”
BackgroundClinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
Lewiecki, E. M., & Laster, A. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1178 · Cited by 201
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions
Chen, L.-R., Ko, N.-Y., & Chen, K.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092213 · Cited by 116
The effects of Tai Chi on bone mineral density in postmenopausal women: a systematic review
Wayne, P. M., Kiel, D. P., Krebs, D. E., Davis, R. B., Savetsky-German, J., Connelly, M., & Buring, J. E. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.02.012 · Cited by 113
Metadata
- Authors
- Schousboe, J. T., Nyman, J. A., Kane, R. L., & Ensrud, K. E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-05-03
- Volume
- 142
- Issue
- 9
- Pages
- 734-741
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1974751798
- Cited by
- 133
- References
- 9
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women. https://app.cochat.ai/papers/10.7326/0003-4819-142-9-200505030-00008
- The paper
- Schousboe, J. T., Nyman, J. A., Kane, R. L., & Ensrud, K. E. (2005). Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-142-9-200505030-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.